Date: 2018-01-04
Type of information: Series A financing round
Company: BioNTech (Germany)
Investors: Redmile Group (USA - CA) Janus Henderson Investors (UK) Invus (USA - NY) Fidelity Management & Research Company (USA - MA) European family offices. The Struengmann Family Office
Amount: $270 million
Funding type: series A financing round
Planned used:
- BioNTech will use the capital to further advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T / T-Cell receptors for the treatment of cancer and other diseases with high medical need. Its corporate partnerships include collaborations with Genentech, a member of the Roche Group, Eli Lilly and Company, Sanofi, Genmab and Bayer Animal Health.
Others:
- • On January 4, 2018, BioNTech, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, announced it has completed a $ 270 million Series A round of financing. The company previously completed a seed round fundraising in 2008 concurrent with its founding.
- The Series A round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Management & Research Company and several European family offices. The Struengmann Family Office, an existing investor in BioNTech, also participated in the capital raise.
Therapeutic area: Cancer - Oncology - Infectious diseases
Is general: Yes
